Boston Trust Walden Corp Has $43.28 Million Position in Medpace Holdings, Inc. (NASDAQ:MEDP)

Boston Trust Walden Corp lowered its holdings in Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) by 17.9% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 129,655 shares of the company's stock after selling 28,296 shares during the quarter. Boston Trust Walden Corp owned 0.42% of Medpace worth $43,279,000 at the end of the most recent quarter.

Several other hedge funds have also recently added to or reduced their stakes in the business. Fidelis Capital Partners LLC acquired a new position in Medpace during the first quarter worth $31,000. J.Safra Asset Management Corp increased its position in shares of Medpace by 87.0% during the 1st quarter. J.Safra Asset Management Corp now owns 101 shares of the company's stock worth $41,000 after purchasing an additional 47 shares in the last quarter. DT Investment Partners LLC bought a new position in Medpace during the 2nd quarter valued at about $41,000. Ashton Thomas Private Wealth LLC acquired a new position in Medpace in the second quarter valued at about $52,000. Finally, EntryPoint Capital LLC bought a new stake in Medpace during the first quarter worth about $54,000. Institutional investors and hedge funds own 77.98% of the company's stock.

Medpace Trading Up 0.7 %

Shares of NASDAQ:MEDP traded up $2.14 during trading on Friday, hitting $330.22. 236,588 shares of the company's stock were exchanged, compared to its average volume of 274,489. The firm has a market cap of $10.24 billion, a P/E ratio of 28.92, a PEG ratio of 1.74 and a beta of 1.35. The firm has a 50-day moving average price of $351.45 and a two-hundred day moving average price of $381.12. Medpace Holdings, Inc. has a 1-year low of $239.00 and a 1-year high of $459.77.

Medpace (NASDAQ:MEDP - Get Free Report) last released its earnings results on Monday, October 21st. The company reported $3.01 EPS for the quarter, topping analysts' consensus estimates of $2.77 by $0.24. The firm had revenue of $533.32 million during the quarter, compared to analyst estimates of $540.99 million. Medpace had a net margin of 17.66% and a return on equity of 50.87%. The business's quarterly revenue was up 8.3% compared to the same quarter last year. During the same quarter in the previous year, the business earned $2.22 EPS. As a group, research analysts predict that Medpace Holdings, Inc. will post 11.77 EPS for the current year.

Analysts Set New Price Targets

A number of research analysts have recently issued reports on MEDP shares. Jefferies Financial Group cut shares of Medpace from a "buy" rating to a "hold" rating and cut their target price for the company from $415.00 to $345.00 in a research note on Wednesday, September 25th. Deutsche Bank Aktiengesellschaft reduced their price objective on Medpace from $395.00 to $336.00 and set a "hold" rating on the stock in a research note on Wednesday, July 24th. Baird R W lowered Medpace from a "strong-buy" rating to a "hold" rating in a research note on Wednesday. StockNews.com cut Medpace from a "buy" rating to a "hold" rating in a report on Friday, September 27th. Finally, William Blair reissued an "outperform" rating on shares of Medpace in a report on Tuesday, October 22nd. Seven equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Hold" and a consensus target price of $380.00.

Medpace Company Profile

Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.